A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Stinchcombe, T. E. [1 ]
Janne, P. A. [2 ]
Wang, X. [3 ]
Bertino, E. M. [4 ]
Weiss, J. M. [5 ]
Bazhenova, L. [6 ]
Gu, L. [3 ]
Lau, C. J. [2 ]
Paweletz, C. P. [2 ]
Jaslowski, A. J. [7 ]
Gerstner, G. J. [8 ]
Baggstrom, M. Q. [9 ]
Graziano, S. L. [10 ]
Beardenlii, J. [11 ]
Vokes, E. E. [12 ]
机构：
[1] Duke Canc Ctr, Med Oncol, Durham, NC USA
[2] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[3] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA
[4] Ohio State Univ, James Canc Hosp, Med Oncol, Columbus, OH 43210 USA
[5] Univ North Carolina Chapel Hill, Hematol Oncol, Chapel Hill, NC USA
[6] Moores UCSD Canc Ctr, Med, La Jolla, CA USA
[7] St Marys Hosp, Med Oncol, Green Bay, WI USA
[8] Illinois CancerCare PC, Med Oncol, Peoria, IL USA
[9] Washington Univ, Sch Med, Med Oncol, St Louis, MO USA
[10] SUNY Upstate Med Univ, Med Oncol, Syracuse, NY 13210 USA
[11] Palmetto Hematol Oncol Associates, Med Oncol, Spartanburg, SC USA
[12] Univ Chicago, Med Ctr, Med Oncol, Chicago, IL 60637 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1444P
引用
收藏
页码：522 / 522
页数：1
相关论文
共 50 条
  • [21] Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
    Spigel, David R.
    Ervin, Thomas J.
    Ramlau, Rodryg A.
    Daniel, Davey B.
    Goldschmidt, Jerome H., Jr.
    Blumenschein, George R., Jr.
    Krzakowski, Maciej J.
    Robinet, Gilles
    Godbert, Benoit
    Barlesi, Fabrice
    Govindan, Ramaswamy
    Patel, Taral
    Orlov, Sergey V.
    Wertheim, Michael S.
    Yu, Wei
    Zha, Jiping
    Yauch, Robert L.
    Patel, Premal H.
    Phan, See-Chun
    Peterson, Amy C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) : 4105 - +
  • [22] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Kobayashi, Takashi
    Koizumi, Tomonobu
    Agatsuma, Toshihide
    Yasuo, Masanori
    Tsushima, Kenji
    Kubo, Keishi
    Eda, Seiichiro
    Kuraishi, Hiroshi
    Koyama, Shigeru
    Hachiya, Tsutomu
    Ohura, Nariaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1241 - 1246
  • [23] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Takashi Kobayashi
    Tomonobu Koizumi
    Toshihide Agatsuma
    Masanori Yasuo
    Kenji Tsushima
    Keishi Kubo
    Seiichiro Eda
    Hiroshi Kuraishi
    Shigeru Koyama
    Tsutomu Hachiya
    Nariaki Ohura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1241 - 1246
  • [24] MODULATION OF THE CYCLOOXYGENASE PATHWAY IS ASSOCIATED WITH EFFICACY IN A RANDOMIZED PHASE II TRIAL OF ERLOTINIB AND CELECOXIB OR PLACEBO IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Fishbein, Michael C.
    Gardner, Brian
    Milne, Ginder L.
    Koczywas, Marianna
    Cristea, Mihaela
    Dowell, Jonathan E.
    Wang, Hejing
    Figlin, Robert A.
    Elashoff, Robert M.
    Dubinett, Steven M.
    Reckamp, Karen L.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1094 - S1094
  • [25] Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression (NCT00503971): The TARZO trial
    Reguart, N.
    Isla, D.
    Cardona, A. F.
    Palmero, R.
    Cardenal, F.
    Rolfo, C.
    Montanes, A.
    Queralt, C.
    Carcereny, E.
    Rosell, R.
    EJC SUPPLEMENTS, 2009, 7 (02): : 550 - 550
  • [26] A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer Cancer
    Minemura H.
    Yokouchi H.
    Azuma K.
    Hirai K.-I.
    Sekine S.
    Oshima K.
    Kanazawa K.
    Tanino Y.
    Inokoshi Y.
    Ishii T.
    Katsuura Y.
    Oishi A.
    Ishida T.
    Munakata M.
    BMC Research Notes, 8 (1)
  • [27] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Soria, J. C.
    Bennouna, J.
    Leighl, N.
    Khuri, F.
    Traynor, A. M.
    Johnson, B.
    Kay, A.
    Blais, N.
    Jehl, V.
    Papadimitrakopoulou, V.
    EJC SUPPLEMENTS, 2009, 7 (02): : 558 - 559
  • [28] A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC)
    Neal, Joel W.
    Wakelee, Heather A.
    Feliciano, Josephine Louella
    Goldberg, Sarah B.
    Morgensztern, Daniel
    Das, Millie Snigdha
    Heist, Rebecca Suk
    Lennes, Inga Tolin
    Muzikansky, Alona
    Edelman, Martin J.
    Gettinger, Scott N.
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Leighl, N. B.
    Soria, J.
    Bennouna, J.
    Blais, N.
    Traynor, A. M.
    Papadimitrakopoulou, V.
    Klimovsky, J.
    Jappe, A.
    Jehl, V.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] VeriStrat predicts survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab
    Salmon, J. S.
    Dang, T. P.
    Billheimer, D.
    Roder, H.
    Grigorieva, J.
    Tsypin, M.
    Herbst, R. S.
    Tsao, A. S.
    Tran, H.
    Carbone, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345